Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.70 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17173215 | 0.86 | HDAC1 (0.54) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2801905 | 0.85 | BCL2L1 (0.59) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL2250510 | 0.84 | HDAC1 (0.69) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL31207866 | 0.84 | HDAC1 (0.69) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL24360345 | 0.84 | HDAC1 (0.68) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL120246 | 0.84 | HDAC1 (0.68) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL10052926 | 0.82 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL464400 | 0.81 | HDAC1 (0.64) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL153980 | 0.81 | MEN1 (0.57) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL17842780 | 0.80 | HDAC1 (0.62) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | claimed |
| EP-2432778-B1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI SAS (IT) | 2013-03-20 | — | — | EP | claimed |
| EP-2432778-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | Malesci Istituto Farmacobiologico S.p.a. (IT) | 2012-03-28 | — | — | EP | claimed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | claimed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | claimed |
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | claimed |
| EP-1809267-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | Laboratori Guidotti S.P.A. (IT) | 2007-07-25 | — | — | EP | claimed |
| US-20060223814-A1 | Nk-2 antagonist basic linear compounds and formulations containing them | MENARINI RICERCHE S.P.A. (IT) | 2006-10-05 | — | — | US | claimed |
| WO-2006045820-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | LABORATORI GUIDOTTI S.P.A. (IT) | 2006-05-04 | — | — | WO | claimed |
| EP-1620432-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2006-02-01 | — | — | EP | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| WO-2004094412-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2004-11-04 | — | — | WO | claimed |
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2006045820-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | LABORATORI GUIDOTTI S.P.A. (IT) | 2006-05-04 | — | — | WO | disclosed |
| EP-1620432-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2006-02-01 | — | — | EP | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| WO-2004094412-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | DDT, BBOX1, IMPDH2 | HDAC1 4611/4885HDAC3 4688/4885HDAC4 4854/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | HDAC1 867/4885HDAC3 2627/4885HDAC4 1767/4885 |
| US-20060223814-A1 | Nk-2 antagonist basic linear compounds and formulations containing them | BDKRB2, KLK2, BDKRB1 | HDAC1 1746/4885HDAC3 2663/4885HDAC4 1950/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | HDAC1 48/4885HDAC3 308/4885HDAC4 935/4885 |
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LDHA, LDHB, SLC6A1 | HDAC1 679/4885HDAC3 316/4885HDAC4 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.